US Stock MarketDetailed Quotes
NRSN NeuroSense Therapeutics
- 0.980
- +0.050+5.41%
Close Nov 29 13:00 ET
- 0.980
- 0.0000.00%
Post 17:01 ET
20.30MMarket Cap-1507P/E (TTM)
1.080High0.908Low323.42KVolume0.940Open0.930Pre Close311.38KTurnover2.05%Turnover RatioLossP/E (Static)20.71MShares2.33052wk High-11.95P/B15.44MFloat Cap0.51252wk Low--Dividend TTM15.76MShs Float8.180Historical High--Div YieldTTM18.54%Amplitude0.400Historical Low0.962Avg Price1Lot Size
NeuroSense Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | (FY)Dec 31, 2019 | |
|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | |||||
| Cash flow from continuing operating activities | -11.42%-8.45M | -392.92%-7.59M | -121.44%-1.54M | -19.42%-695K | -582K |
| Net income from continuing operations | 8.59%-11.28M | -205.37%-12.34M | -42.89%-4.04M | -131.42%-2.83M | ---1.22M |
| Operating gains losses | -103.86%-2.38M | 57.20%-1.17M | ---2.72M | ---- | ---- |
| Depreciation and amortization | 8.99%97K | 2,866.67%89K | 0.00%3K | --3K | ---- |
| Other non cash items | 1,775.00%402K | -103.03%-24K | 39,650.00%791K | ---2K | ---- |
| Change In working capital | 154.40%1.91M | 174.73%750K | 284.51%273K | 144.83%71K | --29K |
| -Change in receivables | -65.45%19K | 126.96%55K | -1,600.00%-204K | -300.00%-12K | ---3K |
| -Change in payables and accrued expense | 171.80%1.89M | 45.70%695K | 474.70%477K | 159.38%83K | --32K |
| Cash from discontinued investing activities | |||||
| Operating cash flow | -11.42%-8.45M | -392.92%-7.59M | -121.44%-1.54M | -19.42%-695K | ---582K |
| Investing cash flow | |||||
| Cash flow from continuing investing activities | 202.97%3.65M | -20,729.41%-3.54M | -88.89%-17K | 65.38%-9K | -26K |
| Net PPE purchase and sale | 58.57%-29K | -311.76%-70K | -88.89%-17K | -28.57%-9K | ---7K |
| Net investment purchase and sale | 200.00%3.5M | ---3.5M | --0 | --0 | ---- |
| Net other investing changes | 85.00%-3K | ---20K | ---- | ---- | ---19K |
| Cash from discontinued investing activities | |||||
| Investing cash flow | 202.97%3.65M | -20,729.41%-3.54M | -88.89%-17K | 65.38%-9K | ---26K |
| Financing cash flow | |||||
| Cash flow from continuing financing activities | 5.41%3.9M | -68.95%3.7M | 2,242.91%11.9M | -64.15%508K | 1.42M |
| Net issuance payments of debt | -1.27%-80K | ---79K | --0 | --0 | ---3K |
| Net common stock issuance | --3.97M | --0 | 1,841.73%9.86M | -64.23%508K | --1.42M |
| Proceeds from stock option exercised by employees | -99.87%5K | 204.85%3.77M | --1.24M | --0 | --0 |
| Net other financing activities | ---- | ---- | --800K | ---- | ---- |
| Cash from discontinued financing activities | |||||
| Financing cash flow | 5.41%3.9M | -68.95%3.7M | 2,242.91%11.9M | -64.15%508K | --1.42M |
| Net cash flow | |||||
| Beginning cash position | -67.97%3.54M | 1,482.69%11.06M | -21.90%699K | 940.70%895K | --86K |
| Current changes in cash | 87.74%-911K | -171.83%-7.43M | 5,378.57%10.35M | -124.23%-196K | --809K |
| Effect of exchange rate changes | 109.09%8K | -588.89%-88K | --18K | --0 | --0 |
| End cash Position | -25.49%2.64M | -67.97%3.54M | 1,482.69%11.06M | -21.90%699K | --895K |
| Free cash flow | -10.78%-8.48M | -392.03%-7.66M | -121.02%-1.56M | -19.52%-704K | ---589K |
| Currency Unit | USD | USD | USD | USD | USD |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | Unqualified Opinion | Unqualified Opinion with Explanatory Notes | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data